Financials
Financial year 2025
Lasev Pharma Consulting from Clavier, company number BE1013507072, closed financial year 2025 with a result of € 53,920 after tax. For that financial year Lasev Pharma Consulting recorded a gross margin of € 78,061 and equity of € 68,160. Compared with financial year 2024, the result moved from € 12,282 to € 53,920. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.
€ 68,160
▲ € 52,879 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 53,920
▲ € 41,638 vs 2024
Profit after tax over the fiscal year.
€ 67,961
▲ € 56,846 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1,041 paid out
2 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 855
▲ 45% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6,354
▲ 161% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,289
▲ 50% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 16,454 | € 78,061 | ▲ € 61,607 |
| Profit after taxes | € 12,282 | € 53,920 | ▲ € 41,638 |
| Equity | € 15,282 | € 68,160 | ▲ € 52,879 |
| Total debts | € 17,185 | € 24,684 | ▲ 44% |
| Cash | € 11,116 | € 67,961 | ▲ € 56,846 |
| Retained profit | € 12,282 | € 65,160 | ▲ € 52,879 |
| Dividend | € 0 | € 1,041 | |
| Balance sheet total | € 32,467 | € 92,844 | ▲ 186% |
Key figures of Lasev Pharma Consulting, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Lasev Pharma Consulting?
What happened at Lasev Pharma Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 53,920 (▲ € 41,638 vs 2024). Source: NBB ↗
- New establishment in Clavier. KBO
- Séverine JASPART became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 12,282 profit in 2024 to € 53,920 profit in 2025.
Paid € 24,829 in corporate taxes since 2024.
Best year ever: 2025, with € 53,920 profit.
Paid out € 1,041 in dividends to the owners in total.
Management
Behind Lasev Pharma Consulting is Séverine JASPART.
Directors
According to the 2025 annual accounts
Séverine JASPART
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Rue des Condruzes 19
4560 Clavier
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1013.507.072
- VAT number
- BE 1013.507.072
- Registered office
- Rue des Condruzes 19, 4560 Clavier
- Names & denominations
- Lasev Pharma Consulting
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 September 2024
- Peppol
- Active · Active since 15 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering